Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 209, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.112861
Keywords
CBP/p300; Bromodomain; HAT; Inhibitors
Categories
Funding
- National Key Grant from Chinese Ministry of Science and Technology [2016YFA0501800]
- National Natural Science Foundation of China [81870297, 81703328]
- Henan Scientific Innovation Talent Team, Department of Education [19IRTSTHN001]
- China Postdoctoral Science Foundation [2020M672249]
Ask authors/readers for more resources
CBP/p300, as a potential target for treating diseases including malignant tumors, has attracted interest in the development of small-molecule inhibitors. The review focuses on the development of CBP/p300 inhibitors from 2010 to 2020, highlighting their structure-activity relationships, binding modes, selectivity, and pharmacological functions to facilitate rational design and development of potential inhibitors.
CBP/p300, functioning as histone acetyltransferases and transcriptional co-factors, represents an attractive target for various diseases, including malignant tumor. The development of small-molecule inhibitors targeting the bromodomain and HAT domains of CBP/p300 has aroused broad interests of medicinal chemist in expectation of providing new hope for anti-cancer treatment. In particular, the CBP/p300 bromodomain inhibitor CCS1477, identified by CellCentric, is currently undergone clinical evaluation for the treatment of haematological malignancies and prostate cancer. In this review, we depict the development of CBP/p300 inhibitors reported from 2010 to 2020 and particularly highlight their structure-activity relationships (SARs), binding modes, selectivity and pharmacological functions with the aim to facilitate rational design and development of CBP/p300 inhibitors. (c) 2020 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available